Trump's FDA Nominee Has Never Worked at the FDA. None of Her Last Three Predecessors Got the Job the Way She's Getting It.

What the job actually covers

The FDA regulates a large share of the American economy: human drugs and biological products including vaccines, medical devices, tobacco products, animal drugs, most of the food supply (everything except meat, poultry, and eggs, which fall to USDA (the U.S. Department of Agriculture)), cosmetics, and electronics that emit radiation. The FDA's own current figure is that it regulates roughly 20 cents of every dollar U.S. consumers spend. Its FY2026 budget is $6.8 billion -- about $3.2 billion in direct federal appropriation and $3.6 billion from industry user fees, and a roughly 4 percent cut from FY2025.

Running it means overseeing drug and device approvals, food-safety enforcement, an agency workforce dealing with real staffing and morale problems (a point Cassidy raised directly), and constant pressure from the industries it regulates and the public health infrastructure that depends on its rulings.

The nominee

Heidi Overton was born in 1989 in Cortez, Colorado. She earned a bachelor's degree from the University of New Mexico in 2011, summa cum laude, and her MD (medical degree) from the University of New Mexico School of Medicine in 2015. She also holds a PhD in Clinical Investigation from Johns Hopkins Bloomberg School of Public Health. She trained in general surgery residency at Johns Hopkins Hospital starting in 2015, and is board-certified -- a real, ABMS-recognized specialty credential (the American Board of Medical Specialties) -- in Public Health and General Preventive Medicine, not surgery. A U.S. News physician directory lists her as a practicing preventive medicine physician based in Washington, D.C.

She was a White House Fellow during Trump's first term, working in the Office of American Innovation and the Domestic Policy Council, including on the federal COVID-19 response. From 2021 to 2025 she led the Center for a Healthy America at the America First Policy Institute, a think tank aligned with Trump. Since January 2025 she's served as Deputy Assistant to the President for Domestic Policy, working closely with HHS (Department of Health and Human Services) Secretary Robert F. Kennedy Jr. and CMS (Centers for Medicare and Medicaid Services) Administrator Dr. Mehmet Oz, and was in the Oval Office when Trump signed an executive order on childhood vaccines in August 2026. She was reportedly offered the CDC director job after Susan Monarez's removal and turned it down.

What isn't in her record, based on everything found for this piece: any period working at or with the FDA, in any capacity; any pharmaceutical, biotech, or medical device industry experience; or any prior role managing an organization on the FDA's scale.

Her three immediate predecessors

Marty Makary, Overton's direct predecessor, was a practicing surgical oncologist at Johns Hopkins, held the Mark Ravitch Chair in Gastrointestinal Surgery there, and led its Islet Transplant Surgery division, before being elected to the National Academy of Medicine in 2018 and confirmed as Commissioner in 2025. He resigned in May 2026 amid what multiple outlets characterized as agency turmoil and a policy dispute over lifting the flavored-vape ban; his own predecessor, Scott Gottlieb, was asked directly on NPR whether Makary had been pushed out by the White House and said he didn't know if that narrative was true, adding that he'd had his own policy disputes with the White House during his tenure but was never forced into a decision. The exact circumstances of Makary's departure remain unresolved.

Before Makary, Robert Califf held the job twice. A cardiologist, he spent his career at Duke -- founding director of the Duke Clinical Research Institute, more than 1,200 peer-reviewed publications -- and had already served as FDA Deputy Commissioner before he was first confirmed as Commissioner in 2016.

Before Califf's second term, Stephen Hahn ran the medicine program at MD Anderson Cancer Center in Houston as its chief medical executive, before being confirmed 72-18 in December 2019. A radiation and medical oncologist trained at Temple and the National Cancer Institute, Hahn had no prior FDA experience of his own -- his qualification for the job was leading one of the country's most prominent cancer centers, not having worked inside the agency.

Between the three of them: Califf had already worked at the FDA. Hahn had led the medical program at a major national institution. Makary was an actively practicing surgeon with a named chair and a divisional leadership title. Based on the record reviewed for this piece, Overton has done none of those three things.

The reaction, on the record

Trump announced the nomination on Truth Social, calling Overton "a ROCKSTAR in my Administration." He has separately said she brings him "solutions that work best for the Country," and said Kennedy has told him she is "ALWAYS RIGHT."

Cassidy, the Senate HELP Committee (Health, Education, Labor and Pensions) chairman, said he respects her experience as a physician but voiced "strong concerns about her nomination," saying "her lack of managerial experience does not prepare her well for leading a large organization" already dealing with "staffing and morale issues." Separately, Cassidy called her role "almost disqualifying" -- specifically her appearance beside Trump at an August 10, 2026 executive order signing that directed splitting the combined measles-mumps-rubella vaccine into three separate shots, a change medical groups have not recommended.

Sen. Patty Murray, the committee's top Democrat, said: "Heidi Overton is a far-right, anti-abortion extremist who has no business leading the FDA," and "The American people deserve someone who will put science and facts first, not another Trump sycophant who will make it their mission to attack medication abortion." That characterization traces to a specific, documented record: in a 2023 policy brief titled "Risking Two Lives -- The Dangerous Rise of Chemical Abortion," Overton called mail-order abortion pills prescribed via telehealth across state lines "Skype abortions" and called on the federal government to end the practice. While at the America First Policy Institute, she also described the Supreme Court's 2022 decision overturning Roe v. Wade as a "huge victory for life" and pushed for tighter limits on mifepristone and misoprostol, the two drugs used in medication abortion. If confirmed, she would be positioned to act on those views through the FDA's own authority over both drugs.

We found no public statement from Overton herself directly responding to the qualifications criticism.

The math

Republicans hold 53 Senate seats and can afford to lose only three votes on the floor, with every Democrat and both independents expected to vote no. That makes Cassidy's position -- and any other Republican senator who shares his concern -- potentially decisive.

What is and isn't established here

Confirmed: Overton's full education and training history; her board certification specialty; her professional history since 2019; her 2023 policy brief and its "Skype abortions" language, and her "huge victory for life" characterization of Dobbs; the credentials of her three immediate predecessors (Makary, Califf, Hahn); the direct quotes from Trump, Cassidy (including "almost disqualifying"), and Murray; and the Senate math.

Not established: whether she has any meaningful ongoing clinical practice beyond what a general directory listing shows; any direct response from Overton to the specific "unqualified" criticism; and, obviously, whether she will be confirmed. This piece takes no position on whether she should be -- it lays out what the job covers, what her three predecessors brought to it, and what she's actually done, and lets the comparison stand on its own.